) The goal of this program is to produce successful clinical oncologist-investigators who can independently design, implement and manage all phases of clinical trials research. The purpose of this program is to prepare highly qualified individuals who are capable of: 1) Communicating and coordinating clinical research activities with basic/behavioral research scientists to expedite translation of scientific findings into patient-oriented research; 2) Performing independent clinical research that develops and tests rational hypotheses based on fundamental and clinical research findings in order to improve the medical cancer of cancer patients or prevent development of cancer in populations at risk; 3) Managing all phases of clinical trials research including designing and implementation of innovative clinical protocols. The specific objectives are to: 1) Provide a flexible career development program for oncology medical doctors and Ph.D. nurses who have completed their clinical training and who are committed to a clinical research career in an academic setting; 2) Foster interdisciplinary training, communication and interaction through multiple mentoring of program scholars; 3) Create an opportunity of ongoing mentorship to support these junior faculty scholar after their formal career development program ends to ensure their successful transition to clinical research independence. Madeleine Kane, MD, PhD, Professor of Medicine (Medical Oncology) will serve as Program Leader. A multidisciplinary Advisory Committee will recruit scholars from various oncology disciplines, oversee their career development programs and evaluate overall program goals with the assistance of an External Review Panel. Individualized training programs, based on a core of required activities, will be developed for each scholar under the direct supervision of a Mentor Committee consisting of a minimum of three faculty (a clinical, prevention/control and basic/behavioral science mentor will be selected for each scholar). The Clinical Oncology Scholars Program will last from two-seven years and mentoring will continue on an informal, ad hoc basis until a scholar achieves academic independence.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
5K12CA086913-05
Application #
6803139
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lei, Ming
Project Start
2000-09-18
Project End
2007-08-31
Budget Start
2004-09-01
Budget End
2007-08-31
Support Year
5
Fiscal Year
2004
Total Cost
$536,240
Indirect Cost
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Kiseljak-Vassiliades, Katja; Zhang, Yu; Bagby, Stacey M et al. (2018) Development of new preclinical models to advance adrenocortical carcinoma research. Endocr Relat Cancer 25:437-451
Courtney, Kevin D; Infante, Jeffrey R; Lam, Elaine T et al. (2018) Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2? Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma. J Clin Oncol 36:867-874
Lam, Elaine T; Eckhardt, S Gail; Messersmith, Wells et al. (2018) Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors. Mol Cancer Ther 17:215-221
Kessler, Elizabeth R; Su, Lih-Jen; Gao, Dexiang et al. (2018) Phase II Trial of Acai Juice Product in Biochemically Recurrent Prostate Cancer. Integr Cancer Ther 17:1103-1108
Bhatia, Shilpa; Griego, Anastacia; Lennon, Shelby et al. (2018) Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor. Mol Cancer Ther 17:2049-2059
Kessler, E R; Gao, D; Flaig, T W et al. (2017) Phase II study of cabazitaxel with or without abiraterone acetate and prednisone in patients with metastatic castrate resistant prostate cancer after prior docetaxel and abiraterone acetate. Ann Oncol 28:668
Campbell, Warren G; Jones, Bernard L; Schefter, Tracey et al. (2017) An evaluation of motion mitigation techniques for pancreatic SBRT. Radiother Oncol 124:168-173
Dorris, Kathleen; Liu, Chunyan; Li, Dandan et al. (2017) A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials. Pediatr Blood Cancer 64:
Carrasco Jr, Alonso; Caldwell, Brian T; Cost, Carrye R et al. (2017) Reliability of intraoperative frozen section for the diagnosis of renal tumors suspicious for malignancy in children and adolescents. Pediatr Blood Cancer 64:
Campbell, Warren G; Miften, Moyed; Olsen, Lindsey et al. (2017) Neural network dose models for knowledge-based planning in pancreatic SBRT. Med Phys 44:6148-6158

Showing the most recent 10 out of 100 publications